Summary
Advantages of magnetic resonance imaging (MRI) in the study of prostatic disease include a precise anatomical display in multiple planes, superb contrast resolution, and differential physicochemical characteristics that are obtained without known toxicity. In practice, however, MRI has not been shown to differentiate consistently between normal and abnormal prostatic tissue. Although normal prostatic and periprostatic anatomy is clearly defined in T1-weighted images, controversy persists as to the precise differential characteristics of inflammatory and neoplastic disease within the prostate. Thus, MRI is not presently adequate for prostate cancer screening. MRI has been shown to be superior to computerized axial tomography (CAT) for pelvic staging of prostate cancer; however, comparative studies involving other modalities with precise histologic confirmation are limited and the improvement reported is modest. There is some evidence that MRI may be helpful in the detection of prostate cancer metastatic to bone, but, again, information is limited. Substantial advances in MRI techniques such as optimal pulse sequencing, surface coils, and, possibly, paramagnetic contrast agents will be required to secure a role for MRI in prostate cancer evaluation.
Similar content being viewed by others
References
Biondetti PR, Lee JKT, Ling D, Catalona WJ (1987) Clinical stage B prostate carcinoma: staging with MR Imaging. Radiology 162:325–329
Bryan PJ, Butler HE, LiPuma JP (1983) NMR scanning of the pelvis: initial experience with 0.3 T system. Am J Roentgenol 141:1111–1118
Bryan PJ, Butler HE, LiPuma JP (1984) Magnetic resonance imaging of the pelvis. Radiol Clin North Am 22:897–915
Bryan PJ, Butler HE, Nelson AD et al. (1986) Magnetic resonance imaging of the prostate. Am J Roentgenol 146:543–548
Buonocore E, Hesemann C, Pavlicek W, Montie J (1984) Clinical and in vitro magnetic resonance imaging of prostatic carcinoma. Am J Roentgenol 143:1267–1272
Carrol CL, Sommer FG, McNeal JE, Stamey TA (1987) The abnormal prostate: MR imaging at 1.5 T with histopathologic correlation. Radiology 163:521–525
Demas BE, Hricak H, Williams RD (1985) Magnetic resonance imaging in the evaluation of urologic malignancies. Semin Urol 3:27–33
Dooms GC, Hricak H, Crooks LE, Higgins CC (1984) Magnetic resonance imaging of the lymph nodes: comparison with CT. Radiology 153:719–728
Hricak H, Williams RD, Spring DB et al. (1983) Anatomy and pathology of the male pelvis by magnetic resonance imaging. Am J Roentgenol 141:1101–1110
Hricak H, Dooms GC, Jeffrey RB et al. (1987) Prostatic carcinoma: staging by clinical assessment, CT, and MR imaging. Radiology 162:331–336
Kulkarni MV, Shaff MI, Carter MM et al. (1985) Magnetic resonance imaging of the pelvis. Radio Graphics 5:611–625
Larkin BT, Berquist TH, Utz DC (1986) Evaluation of the prostate by magnetic resonance imaging. Magn Reson Imaging 4:53–58
Lee JKT, Rholl KS (1986) MRI of the bladder and prostate. Am J Roentgenol 147:732–736
Ling D, Lee JKT, Heiken JP et al. (1986) Prostatic carcinoma and benign prostatic hyperplasia; inability or MR imaging to distinguish between the two diseases. Radiology 158:103–107
McNeal JE (1983) The prostate gland: morphology and pathology. Monogr Urol 4:3–33
Mukamel E, Hannah J, Zoran B, DeKernion JB (1986) The value of computerized tomography scan and magnetic resonance imaging in staging prostatic carcinoma: comparison with the clinical and histological staging. J Urol 136:1231–1233
Poon PY, McCallum RW, Henkelman MM et al. (1985) Magnetic resonance imaging of the prostate. Radiology 154:143–149
Steyn JH, Smith FW (1982) Nuclear magnetic resonance imaging of the prostate. Br J Urol 54:726–728
Williams RD, Hricak H (1984) Magnetic resonance imaging in urology. J Urol 132:641–649
Williams RD, Dunn V, Abu-Yousef M, Brown C (1986) Staging of pelvic malignancies by MRI (Abstract 482). J Urol 135:224
Author information
Authors and Affiliations
Rights and permissions
About this article
Cite this article
Kwon, E.D., Williams, R.D. Magnetic resonance imaging in the evaluation of prostate cancer. World J Urol 7, 17–21 (1989). https://doi.org/10.1007/BF01576839
Issue Date:
DOI: https://doi.org/10.1007/BF01576839